Respirology : official journal of the Asian Pacific Society of Respirology
-
Randomized Controlled Trial
Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial.
Roflumilast, an oral, selective phosphodiesterase 4 inhibitor, has been shown to reduce exacerbations and improve pulmonary function in patients with COPD. This study examined the efficacy, safety and tolerability of roflumilast in Asian patients with COPD. ⋯ Roflumilast, 500 µg once daily, improves pulmonary function in Asian patients with COPD. The safety and tolerability of roflumilast in this population was similar to that in a Caucasian population.